Description : Teneligliptin is a Novel Dipeptidyl Peptidase IV inhibitors for the treatment of type 2 diabetes with minimal risk of hypoglycemia and weight gain. TENeLIgliptin act on inCRETins with elevation of activated glucagon-like peptide 1 (GLP-1) levels and the resulting suppression of postprandial hyperglycemia.